Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Translational Therapeutics

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma

British Journal of Cancer volume 125, pages 1365–1376 (2021)Cite this article

Subjects

Abstract

Background

There is no effective therapy for patients with malignant pleural mesothelioma (MPM) who progressed to platinum-based chemotherapy and immunotherapy.

Methods

We aimed to investigate the antitumor activity of CDK4/6 inhibitors using in vitro and in vivo preclinical models of MPM.

Results

Based on publicly available transcriptomic data of MPM, patients with CDK4 or CDK6 overexpression had shorter overall survival. Treatment with abemaciclib or palbociclib at 100 nM significantly decreased cell proliferation in all cell models evaluated. Both CDK4/6 inhibitors significantly induced G1 cell cycle arrest, thereby increasing cell senescence and increased the expression of interferon signalling pathway and tumour antigen presentation process in culture models of MPM. In vivo preclinical studies showed that palbociclib significantly reduced tumour growth and prolonged overall survival using distinct xenograft models of MPM implanted in athymic mice.

Conclusions

Treatment of MPM with CDK4/6 inhibitors decreased cell proliferation, mainly by promoting cell cycle arrest at G1 and by induction of cell senescence. Our preclinical studies provide evidence for evaluating CDK4/6 inhibitors in the clinic for the treatment of MPM.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Quantification of the expression levels of key cell cycle regulators and response to treatment with CDK4/6 inhibitors in a panel of commercial MPM cell lines and primary patient-derived cultures.
Fig. 2: Effects of CDK4/6 inhibitors in cell cycle and cell senescence in MPM cell lines.
Fig. 3: In vivo treatment with palbociclib in MSTO-211H subcutaneous xenografted MPM model.
Fig. 4: In vivo treatment with CDK4/6 inhibitors in advanced orthotopic MPM models.
Fig. 5: Overall survival analysis according to CDK4 and CDK6 expression in two cohorts of patients with MPM.

Similar content being viewed by others

Data availability

All data generated or analysed during this study will be stored in EGA and available on reasonable request.

References

  1. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89:716–24, 24A–24C.

    Article  Google Scholar 

  2. Chen T, Sun XM, Wu L. High time for complete ban on asbestos use in developing countries. JAMA Oncol. 2019;5:779–80.

    Article  Google Scholar 

  3. Hassan R, Morrow B, Thomas A, Walsh T, Lee MK, Gulsuner S, et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci USA. 2019;116:9008–13.

    Article  CAS  Google Scholar 

  4. Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J Clin Oncol. 2018;36:2863–71.

    Article  CAS  Google Scholar 

  5. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43:1022–5.

    Article  CAS  Google Scholar 

  6. Guo R, DuBoff M, Jayakumaran G, Kris MG, Ladanyi M, Robson ME, et al. Novel germline mutations in DNA damage repair in patients with malignant pleural mesotheliomas. J Thorac Oncol. 2020;15:655–60.

    Article  CAS  Google Scholar 

  7. Zauderer MG, Jayakumaran G, DuBoff M, Zhang L, Francis JH, Abramson DH, et al. Prevalence and preliminary validation of screening criteria to identify carriers of germline BAP1 mutations. J Thorac Oncol. 2019;14:1989–94.

    Article  CAS  Google Scholar 

  8. Woolhouse I, Bishop L, Darlison L, de Fonseka D, Edey A, Edwards J, et al. BTS guideline for the investigation and management of malignant pleural mesothelioma. BMJ Open Respir Res. 2018;5:e000266.

    Article  Google Scholar 

  9. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.

    Article  CAS  Google Scholar 

  10. Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405–14.

    Article  CAS  Google Scholar 

  11. Popat S, Curioni-Fontecedro A, Dafni U, Shah R, O’Brien M, Pope A, et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol. 2020;31:1734–45.

    Article  CAS  Google Scholar 

  12. Fennel DO, Ottensmeier C, Califano R, Hanna GG, Ewings S, Hill K, et al. Nivolumab versus placebo in relapsed malignant mesothelioma: preliminary results from the CONFIRM phase 3 trial. In: Presented at: International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer_Abstract PS01.11. 2020.

  13. Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375–86.

    Article  CAS  Google Scholar 

  14. Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407–16.

    Article  CAS  Google Scholar 

  15. Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018;8:1548–65.

    Article  CAS  Google Scholar 

  16. Björkqvist AM, Tammilehto L, Anttila S, Mattson K, Knuutila S. Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer. 1997;75:523–7.

    Article  Google Scholar 

  17. López-Ríos F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 2006;66:2970–9.

    Article  Google Scholar 

  18. Dacic S, Kothmaier H, Land S, Shuai Y, Halbwedl I, Morbini P, et al. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch. 2008;453:627–35.

    Article  Google Scholar 

  19. Hylebos M, Van Camp G, van Meerbeeck JP, Op de Beeck K. The genetic landscape of malignant pleural mesothelioma: results from massively parallel sequencing. J Thorac Oncol. 2016;11:1615–26.

    Article  Google Scholar 

  20. Frizelle SP, Grim J, Zhou J, Gupta P, Curiel DT, Geradts J, et al. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene. 1998;16:3087–95.

    Article  CAS  Google Scholar 

  21. Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, et al. The National Lung Matrix Trial of personalized therapy in lung cancer. Nature. 2020;583:807–12.

    Article  CAS  Google Scholar 

  22. Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 2016;6:353–67.

    Article  CAS  Google Scholar 

  23. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35.

    Article  CAS  Google Scholar 

  24. Turner NC, Huang Bartlett C, Cristofanilli M. Palbociclib in hormone-receptor-positive advanced breast cancer. N. Engl J Med. 2015;373:1672–3.

    Article  Google Scholar 

  25. Oie HK, Russell EK, Carney DN, Gazdar AF. Cell culture methods for the establishment of the NCI series of lung cancer cell lines. J Cell Biochem Suppl. 1996;24:24–31.

    Article  CAS  Google Scholar 

  26. Nadal E, Chen G, Gallegos M, Lin L, Ferrer-Torres D, Truini A. Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma. Clin Cancer Res. 2013;19:6842–52.

    Article  CAS  Google Scholar 

  27. Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian CB, Roberto MP, et al. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 2017;66:1286–96.

    Article  CAS  Google Scholar 

  28. Püschel F, Muñoz-Pinedo C. Measuring the activation of cell death pathways upon inhibition of metabolism. Methods Mol Biol. 2019;1862:163–72.

    Article  Google Scholar 

  29. Bonelli MA, Digiacomo G, Fumarola C, Alfieri R, Quaini F, Falco A. et al. Combined inhibition of CDK4/6 and PI3K/AKT/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells. Neoplasia. 2017;19:637–48.

    Article  CAS  Google Scholar 

  30. Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2020.

  31. Ambrogio C, Carmona FJ, Vidal A, Falcone M, Nieto P, Romero OA, et al. Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts. Cancer Res. 2014;74:5978–88.

    Article  CAS  Google Scholar 

  32. Campisi J, d’Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007;8:729–40.

    Article  CAS  Google Scholar 

  33. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77.

    Article  Google Scholar 

  34. Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548:471–5.

    Article  CAS  Google Scholar 

  35. Salvador-Barbero B, Alvarez-Fernández M, Zapatero-Solana E, El Bakkali A, Menéndez MDC, López-Casas PP, et al. CDK4/6 inhibitors impair recovery from cytotoxic chemotherapy in pancreatic adenocarcinoma. Cancer Cell. 2020;38:584.

    Article  CAS  Google Scholar 

  36. Ruscetti M, Leibold J, Bott MJ, Fennell M, Kulick A, Salgado NR, et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science. 2018;362:1416–22.

    Article  CAS  Google Scholar 

  37. Wagner V, Gil J. Senescence as a therapeutically relevant response to CDK4/6 inhibitors. Oncogene. 2020;39:5165–76.

    Article  CAS  Google Scholar 

  38. Bezzi M, Teo SX, Muller J, Mok WC, Sahu SK, Vardy LA, et al. Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery. Genes Dev. 2013;27:1903–16.

    Article  CAS  Google Scholar 

  39. AbuHammad S, Cullinane C, Martin C, Bacolas Z, Ward T, Chen H, et al. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. Proc Natl Acad Sci USA. 2019;116:17990–8000.

    Article  CAS  Google Scholar 

  40. Varin E, Denoyelle C, Brotin E, Meryet-Figuière M, Giffard F, Abeilard E, et al. Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. Carcinogenesis. 2010;31:984–93.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank CERCA Programme/Generalitat de Catalunya for their institutional support and grant 2017SGR448.

Funding

EN received support from the SLT006/17/00127 grant, funded by the Department of Health of the Generalitat de Catalunya by the call “Acció instrumental d’intensificació de professionals de la salut”. This study was supported by grants from Instituto de Salud Carlos III (grants PI14/01109 and PI18/00920) (co-funded by European Regional Development Fund. ERDF, a way to build Europe), Spanish Society of Medical Oncology grant for emerging research groups and from Pfizer (WI244174) to EN. MH-M was supported by a Marie Skłodowska-Curie grant, agreement no. 766214.

Author information

Authors and Affiliations

  1. Preclinical and Experimental Research in Thoracic Tumors (PrETT) group. Oncobell Program. Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat (Barcelona), Barcelona, Spain

    Elisabet Aliagas, Ania Alay, Miguel Hernández-Madrigal, David Cordero, Mireia Gausachs, Ramón Palmero, Cristina Muñoz-Pinedo, Xavi Solé & Ernest Nadal

  2. Unit of Bioinformatics for Precision Oncology, Catalan Institute of Oncology (ICO), L’Hospitalet de Llobregat (Barcelona), Barcelona, Spain

    Ania Alay, David Cordero & Xavi Solé

  3. Chemoresistance group. Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat (Barcelona), Barcelona, Spain

    Maria Martínez-Iniesta & Alberto Villanueva

  4. Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Barcelona, Spain

    David Cordero & Xavi Solé

  5. Cancer Genetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Badalona, Barcelona, Spain

    Eva Pros, Maria Saigí & Montse Sánchez-Céspedes

  6. Department of Genetics and Genome Biology, Leicester Cancer Research Centre, University of Leicester, Leicester, UK

    Sara Busacca & Dean Fennell

  7. University of Sheffield Teaching Hospitals, Sheffield, UK

    Annabel J. Sharkley

  8. Department of Thoracic Surgery, Glenfield Hospital, Leicester, UK

    Alan Dawson

  9. Department of Medical Oncology, Catalan Institute of Oncology, L’Hospitalet de Llobregat (Barcelona), Barcelona, Spain

    Ramón Palmero, José C. Ruffinelli & Ernest Nadal

  10. Department of Respiratory Medicine, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat (Barcelona), Barcelona, Spain

    Susana Padrones & Samantha Aso

  11. Department of Thoracic Surgery, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat (Barcelona), Barcelona, Spain

    Ignacio Escobar & Ricard Ramos

  12. Department of Pathology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat (Barcelona), Barcelona, Spain

    Roger Llatjós, August Vidal, Eduard Dorca & Mar Varela

  13. Mesothelioma Research Programme, Department of Genetics and Genome Biology, University of Leicester, Leicester, UK

    Dean Fennell

  14. Department of Clinical Sciences, School of Medicine and Health Sciences, Universitat de Barcelona, L’Hospitalet del Llobregat (Barcelona), Campus Bellvitge, Barcelona, Spain

    Ernest Nadal

Authors
  1. Elisabet Aliagas
    View author publications

    Search author on:PubMed Google Scholar

  2. Ania Alay
    View author publications

    Search author on:PubMed Google Scholar

  3. Maria Martínez-Iniesta
    View author publications

    Search author on:PubMed Google Scholar

  4. Miguel Hernández-Madrigal
    View author publications

    Search author on:PubMed Google Scholar

  5. David Cordero
    View author publications

    Search author on:PubMed Google Scholar

  6. Mireia Gausachs
    View author publications

    Search author on:PubMed Google Scholar

  7. Eva Pros
    View author publications

    Search author on:PubMed Google Scholar

  8. Maria Saigí
    View author publications

    Search author on:PubMed Google Scholar

  9. Sara Busacca
    View author publications

    Search author on:PubMed Google Scholar

  10. Annabel J. Sharkley
    View author publications

    Search author on:PubMed Google Scholar

  11. Alan Dawson
    View author publications

    Search author on:PubMed Google Scholar

  12. Ramón Palmero
    View author publications

    Search author on:PubMed Google Scholar

  13. José C. Ruffinelli
    View author publications

    Search author on:PubMed Google Scholar

  14. Susana Padrones
    View author publications

    Search author on:PubMed Google Scholar

  15. Samantha Aso
    View author publications

    Search author on:PubMed Google Scholar

  16. Ignacio Escobar
    View author publications

    Search author on:PubMed Google Scholar

  17. Ricard Ramos
    View author publications

    Search author on:PubMed Google Scholar

  18. Roger Llatjós
    View author publications

    Search author on:PubMed Google Scholar

  19. August Vidal
    View author publications

    Search author on:PubMed Google Scholar

  20. Eduard Dorca
    View author publications

    Search author on:PubMed Google Scholar

  21. Mar Varela
    View author publications

    Search author on:PubMed Google Scholar

  22. Montse Sánchez-Céspedes
    View author publications

    Search author on:PubMed Google Scholar

  23. Dean Fennell
    View author publications

    Search author on:PubMed Google Scholar

  24. Cristina Muñoz-Pinedo
    View author publications

    Search author on:PubMed Google Scholar

  25. Alberto Villanueva
    View author publications

    Search author on:PubMed Google Scholar

  26. Xavi Solé
    View author publications

    Search author on:PubMed Google Scholar

  27. Ernest Nadal
    View author publications

    Search author on:PubMed Google Scholar

Contributions

EA: conceptualisation, methodology, validation, formal analysis, investigation, resources, data curation, writing—original draft, writing—review and editing, visualisation. AA: conceptualisation, software, validation, formal analysis, resources, data curation, writing—review and editing, visualisation. MM-I: methodology, investigation, resources, data curation. MH-M: methodology, validation, investigation, data curation. DC: conceptualisation, software, validation, formal analysis, data curation. MG: conceptualisation, resources, writing—review and editing. EP: resources, writing—review and editing. MS: resources, writing—review and editing. SB: software, validation, data curation. AJS: resources, writing—review and editing. AD: resources, writing—review and editing. RP: resources, data curation, writing—review and editing. SP: resources, writing—review and editing. SA: resources, writing—review and editing. IE: resources, writing—review and editing. RR: resources, writing—review and editing. RL: resources, validation, data curation. AV: resources, validation, data curation. ED: data curation. MV: resources, validation, data curation. MS-C: resources, writing—review and editing. DF: resources, validation, formal analysis, investigation, data curation, writing—review and editing. CM-P: conceptualisation, methodology, validation, formal analysis, investigation, data curation, writing—review and editing, visualisation. AV: conceptualisation, methodology, validation, formal analysis, investigation, data curation, writing—review and editing, visualisation. XS: conceptualisation, software, formal analysis, data curation, writing—review and editing, visualisation. EN: conceptualisation, methodology, validation, formal analysis, investigation, resources, data curation, writing—original draft, writing—review and editing, visualisation, supervision, project administration, funding acquisition.

Corresponding author

Correspondence to Ernest Nadal.

Ethics declarations

Competing interests

EN received research support from Roche, Pfizer, Bristol Myers Squibb and Merck Serono and participated in advisory boards from Bristol Myers Squibb, Merck Serono, Merck Sharpe & Dohme, Lilly, Roche, Pfizer, Takeda, Boehringer Ingelheim, Bayer, Amgen and Astra Zeneca. RP has participated in advisory boards from Bristol Myers Squibb, Merck Sharpe & Dohme, Roche, Pfizer, Lilly, Boehringer Ingelheim and Astra Zeneca. DF has received research support from Astex Therapeutics, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Merck Sharpe & Dohme, Lilly Oncology, Roche and participated in advisory boards from Atara Therapeutics, Bayer, Boehringer Ingelheim and Inventiva. The other authors declare no competing interests.

Ethics approval and consent to participate

The retrospective cohort was approved by a National Ethical Committee, under the references 4/LO/1527 (a translational research platform entitled Predicting Drug and Radiation Sensitivity in Thoracic Cancers—also approved by University Hospitals of Leicester NHS Trust under the reference IRAS131283) and 14/EM/1159 (retrospective cohort). Pleural effusions samples were obtained after patients signed the informed consent approved by the Hospital de Bellvitge Ethical Committee (PR152/14). All the animal experiments were performed in accordance with protocols approved by Animal Research Ethics Committee at IDIBELL. This study was performed in accordance with the principles outlined in the Declaration of Helsinki.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aliagas, E., Alay, A., Martínez-Iniesta, M. et al. Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma. Br J Cancer 125, 1365–1376 (2021). https://doi.org/10.1038/s41416-021-01547-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41416-021-01547-y

Search

Advanced search

Quick links